Select Page
B-Cell Lymphoma Drug Receives FDA Priority Review

B-Cell Lymphoma Drug Receives FDA Priority Review

ADC Therapeutic’s Biologics License was approved by the U.S. Food and Drug Administration (FDA) for their relapsed/refractory diffuse large B-cell Lymphoma drug candidate. The antibody conjugate drug, that catalyzes cancer cell death is being investigated in a...
Treatment Resistant Depression

Treatment Resistant Depression

Treatment resistant depression (TRD) describes various forms of depression that have undergone treatment and seen minimal, if any, long-term positive results. With depression affecting 6.7% of the United States’ population and over 300 million people worldwide, the...
Brilanta by AstraZeneca Approved to Reduce Risk of Stroke

Brilanta by AstraZeneca Approved to Reduce Risk of Stroke

Brilanta was approved by the U.S. Food and Drug Administration (FDA) for its efficacy in reducing the risk of stroke in patients with acute-ischemic stroke based on the Phase 3 THALES Trial. Compared to aspirin alone, when taken with Brilanta there was a clinically...